Related Experiment Video
Updated: Jan 22, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Pulmonary Alveolar Microlithiasis Coexisting With Rheumatic Heart Disease and Severe Pulmonary Hypertension: A Case
Aadithya Shyllesh H1, Tehsim A Memon2, Pranathi Guruswamy1
1Internal Medicine, Ramaiah Medical College Hospital, Ramaiah University of Applied Sciences, Bengaluru, IND.
This case highlights a rare instance of Pulmonary Alveolar Microlithiasis (PAM) coexisting with rheumatic heart disease (RHD). Early recognition of dual pathology is crucial for managing severe pulmonary hypertension in complex cardiopulmonary cases.
Area of Science:
- Pulmonology
- Cardiology
- Genetics
Background:
- Pulmonary Alveolar Microlithiasis (PAM) is a rare lung disease causing calcium phosphate buildup.
- Rheumatic heart disease (RHD) can lead to severe pulmonary hypertension.
- Coexistence of PAM and RHD is exceptionally rare.
More Related Videos
07:41A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...